{"id":"single-dose-quadrivalent-influenza-vaccine","safety":{"commonSideEffects":[{"rate":"null","effect":"Pain, redness, or swelling at the injection site"},{"rate":"null","effect":"Fatigue"},{"rate":"null","effect":"Headache"},{"rate":"null","effect":"Muscle pain"},{"rate":"null","effect":"Fever"}]},"_chembl":{"chemblId":"CHEMBL2109042","moleculeType":"Vaccine component"},"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"The quadrivalent influenza vaccine contains inactivated viruses that stimulate the body's immune system to produce antibodies and immune cells that can recognize and fight the viruses. This immune response helps to protect against influenza infection.","oneSentence":"This vaccine induces an immune response against four different influenza viruses.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:34:42.735Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Prevention of influenza disease caused by four different strains of the influenza virus"}]},"trialDetails":[{"nctId":"NCT07485855","phase":"PHASE3","title":"Influenza Vaccination Strategy for Patients With Hematologic Malignancy","status":"RECRUITING","sponsor":"Asan Medical Center","startDate":"2025-12-04","conditions":"Hematologic Neoplasms, Influenza, Immunogenicity","enrollment":60},{"nctId":"NCT05397223","phase":"PHASE1","title":"A Study of Modified mRNA Vaccines in Healthy Adults","status":"COMPLETED","sponsor":"ModernaTX, Inc.","startDate":"2022-05-24","conditions":"SARS-CoV-2, Seasonal Influenza, Respiratory Syncytial Virus","enrollment":308},{"nctId":"NCT06431607","phase":"PHASE2","title":"A Study to Find the Dose and Assess the Immune Response and Safety of a Vaccine Against Influenza in Healthy Younger and Older Adults","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2024-05-23","conditions":"Influenza, Human","enrollment":845},{"nctId":"NCT05294588","phase":"PHASE2","title":"Efficacy of Immunization With 4C-MenB in Preventing Experimental Urethral Infection With Neisseria Gonorrhoeae","status":"COMPLETED","sponsor":"University of North Carolina, Chapel Hill","startDate":"2022-04-18","conditions":"Gonorrhea Male","enrollment":65},{"nctId":"NCT04164212","phase":"PHASE4","title":"Live Attenuated Influenza Vaccine as a Nasal Model for Influenza Infection","status":"COMPLETED","sponsor":"University of Alabama at Birmingham","startDate":"2020-09-01","conditions":"Influenza","enrollment":33},{"nctId":"NCT07421037","phase":"PHASE1","title":"Clinical Trial of Quadrivalent Subunit Influenza Vaccine (Adjuvant) in Chinese Population Aged 65 Years and Older","status":"ACTIVE_NOT_RECRUITING","sponsor":"Ab&B Bio-tech Co., Ltd.JS","startDate":"2025-11-13","conditions":"Influenza, Influenza Vaccine","enrollment":80},{"nctId":"NCT07111078","phase":"PHASE1","title":"Quadrivalent Influenza HA Stem Vaccine VRC-FLUMOS0122-00-VP (SteMos1) With and Without ALFQ Adjuvant in Healthy Adults","status":"RECRUITING","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2025-08-27","conditions":"Influenza Prevention, Pandemic Influenza Prevention","enrollment":56},{"nctId":"NCT06850051","phase":"PHASE1","title":"A Study on the Safety and Immunogenicity of Influenza, Respiratory Syncytial Virus, Human Metapneumovirus and Parainfluenza Vaccines in Adults 18 to 49 Years of Age.","status":"COMPLETED","sponsor":"Sanofi","startDate":"2025-03-19","conditions":"Healthy Volunteers, Influenza Vaccination, Respiratory Syncytial Virus Vaccination","enrollment":270},{"nctId":"NCT06436703","phase":"PHASE2","title":"A Study About Modified RNA Vaccines Against Influenza in Healthy Adults","status":"COMPLETED","sponsor":"Pfizer","startDate":"2024-05-23","conditions":"Influenza, Human","enrollment":1202},{"nctId":"NCT05330975","phase":"PHASE3","title":"A Study of mRNA-1345 Vaccine Targeting Respiratory Syncytial Virus (RSV) in Adults ≥50 Years of Age","status":"COMPLETED","sponsor":"ModernaTX, Inc.","startDate":"2022-04-01","conditions":"Respiratory Syncytial Virus","enrollment":3317},{"nctId":"NCT05827926","phase":"PHASE1, PHASE2","title":"A Study of mRNA-based Influenza and SARS-CoV-2 (COVID-19) Multi-component Vaccines in Healthy Adults","status":"COMPLETED","sponsor":"ModernaTX, Inc.","startDate":"2023-04-14","conditions":"SARS-CoV-2, Influenza","enrollment":1758},{"nctId":"NCT06694025","phase":"","title":"Post-marketing Surveillance Study for the Safety of Efluelda Tetra Pre-filled Syringe.","status":"NOT_YET_RECRUITING","sponsor":"Sanofi","startDate":"2026-10-01","conditions":"Immunization, Influenza (Healthy Volunteers)","enrollment":670},{"nctId":"NCT05606965","phase":"PHASE2","title":"A Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1010 in Healthy Adults","status":"COMPLETED","sponsor":"ModernaTX, Inc.","startDate":"2022-11-02","conditions":"Influenza","enrollment":172},{"nctId":"NCT03598439","phase":"PHASE4","title":"Randomized Influenza Vaccine Evaluation of Immune Response","status":"COMPLETED","sponsor":"Marshfield Clinic Research Foundation","startDate":"2018-07-30","conditions":"Influenza","enrollment":366},{"nctId":"NCT05755620","phase":"PHASE1","title":"A Study to Evaluate the Safety and Immunogenicity of a Single Dose of H1ssF-3928 mRNA-LNP in Healthy Adults","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2023-04-05","conditions":"Influenza","enrollment":50},{"nctId":"NCT04537234","phase":"PHASE3","title":"Study to Assess the Immune Response and the Safety Profile of a High-Dose Quadrivalent Influenza Vaccine (QIV-HD) Compared to a Standard-Dose Quadrivalent Influenza Vaccine (QIV-SD) in Taiwanese Adults 65 Years of Age and Older","status":"COMPLETED","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2020-11-10","conditions":"Influenza (Healthy Volunteers)","enrollment":165},{"nctId":"NCT04498832","phase":"PHASE3","title":"Study to Assess the Immune Response and the Safety Profile of a High-Dose Quadrivalent Influenza Vaccine (QIV-HD) Compared to a Standard-Dose Quadrivalent Influenza Vaccine (QIV-SD) in Japanese Adults 60 Years of Age and Older","status":"COMPLETED","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2020-10-21","conditions":"Influenza Immunization, Healthy Volunteers","enrollment":2100},{"nctId":"NCT04137887","phase":"PHASE3","title":"Study to Evaluate the Effectiveness of a High-Dose Quadrivalent Influenza Vaccine (QIV-HD) Compared to a Standard-Dose Quadrivalent Influenza Vaccine (QIV-SD) in Adults 65 Years of Age and Older","status":"TERMINATED","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2019-11-04","conditions":"Influenza (Healthy Volunteers)","enrollment":33096},{"nctId":"NCT05517174","phase":"PHASE4","title":"A Pragmatic Randomized Trial to Evaluate the Effectiveness of High-Dose Quadrivalent Influenza Vaccine vs. Standard-Dose Quadrivalent Influenza Vaccine in Older Adults","status":"COMPLETED","sponsor":"Tor Biering-Sørensen","startDate":"2022-09-22","conditions":"Influenza","enrollment":332438},{"nctId":"NCT06506812","phase":"PHASE4","title":"Pooled Analysis of Methodologically Harmonized Pragmatic Randomized Trials of High-Dose vs. Standard-Dose Influenza Vaccine Against Severe Clinical Outcomes","status":"COMPLETED","sponsor":"Tor Biering-Sørensen","startDate":"2025-05-31","conditions":"Influenza","enrollment":466320},{"nctId":"NCT04969276","phase":"PHASE2","title":"Study of a Quadrivalent High-Dose Influenza Vaccine and a Moderna COVID-19 Vaccine Administered Either Concomitantly or Singly in Participants 65 Years of Age and Older Previously Vaccinated With a 2-dose Schedule of Moderna COVID-19 Vaccine","status":"COMPLETED","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2021-07-16","conditions":"Influenza Immunization, Healthy Volunteers","enrollment":306},{"nctId":"NCT04024228","phase":"PHASE3","title":"Study to Assess the Immune Response and the Safety Profile of a High-Dose Quadrivalent Influenza Vaccine (QIV-HD) Compared to a Standard-Dose Quadrivalent Influenza Vaccine (QIV-SD) in Europeans Adults 60 Years of Age and Older","status":"COMPLETED","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2019-10-28","conditions":"Influenza Immunization, Healthy Volunteers","enrollment":1539},{"nctId":"NCT05513391","phase":"PHASE3","title":"Study With Quadrivalent Recombinant Influenza Vaccine (RIV4) Compared With Egg-Based Quadrivalent Influenza Vaccine (IIV4) in Participants Aged 3 to 8 Years","status":"TERMINATED","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2022-11-10","conditions":"Influenza Immunization","enrollment":366},{"nctId":"NCT04144179","phase":"PHASE1","title":"Safety and Immunogenicity of Quadrivalent Recombinant Influenza Vaccine Formulations Containing Different H3 Hemagglutinin Antigens in Healthy Adult Subjects 18 to 30 Years of Age","status":"COMPLETED","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2019-11-06","conditions":"Influenza","enrollment":150},{"nctId":"NCT05827978","phase":"PHASE3","title":"Study of mRNA-1010 Seasonal Influenza Vaccine in Adults","status":"COMPLETED","sponsor":"ModernaTX, Inc.","startDate":"2023-04-17","conditions":"Seasonal Influenza","enrollment":8411},{"nctId":"NCT06361875","phase":"PHASE1, PHASE2","title":"A Study to Investigate the Safety and Immunogenicity of the Quadrivalent Influenza mRNA Vaccines in Adults Aged 18 Years and Above","status":"COMPLETED","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2024-04-01","conditions":"Influenza Immunization","enrollment":910},{"nctId":"NCT06744205","phase":"PHASE1, PHASE2","title":"A Study on the Safety and Immunogenicity of Hexavalent Influenza mRNA Vaccine in Adult Participants 50 Years of Age and Older","status":"ACTIVE_NOT_RECRUITING","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2025-01-06","conditions":"Influenza, Healthy Volunteers","enrollment":1162},{"nctId":"NCT04487041","phase":"PHASE4","title":"Tfh Dysfunction in HIV and Aging","status":"RECRUITING","sponsor":"University of Miami","startDate":"2020-10-30","conditions":"Human Influenza","enrollment":400},{"nctId":"NCT06054269","phase":"PHASE3","title":"Clinical Trial to Evaluate the Immunogenicity of an Adjuvanted Influenza Vaccine Among HCP","status":"ACTIVE_NOT_RECRUITING","sponsor":"Centers for Disease Control and Prevention","startDate":"2022-11-04","conditions":"Influenza","enrollment":192},{"nctId":"NCT05071313","phase":"PHASE3","title":"A Study of an Ad26.RSV.preF-based Vaccine and High-dose Seasonal Influenza Vaccine, With and Without Coadministration, in Adults Aged 65 Years and Older","status":"COMPLETED","sponsor":"Janssen Vaccines & Prevention B.V.","startDate":"2021-10-04","conditions":"Influenza, Human Prevention, Respiratory Syncytial Viruses Prevention","enrollment":777},{"nctId":"NCT05091307","phase":"PHASE3","title":"A Study of Ad26.COV2.S and Influenza Vaccines in Healthy Adults","status":"COMPLETED","sponsor":"Janssen Vaccines & Prevention B.V.","startDate":"2021-11-02","conditions":"COVID-19 Prevention","enrollment":861},{"nctId":"NCT05540522","phase":"PHASE3","title":"A Study to Evaluate a Modified RNA Vaccine Against Influenza in Adults 18 Years of Age or Older","status":"COMPLETED","sponsor":"Pfizer","startDate":"2022-09-12","conditions":"Influenza, Human","enrollment":45789},{"nctId":"NCT05648357","phase":"PHASE4","title":"A Study to Assess the Safety and Immune Response of Quadrivalent Seasonal Influenza Vaccine (Fluarix Tetra) in Participants Aged 65 Years and Older in India","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2023-12-14","conditions":"Influenza, Human","enrollment":250},{"nctId":"NCT05650554","phase":"PHASE1, PHASE2","title":"Safety and Immunogenicity of Quadrivalent Influenza mRNA Vaccine MRT5413 in Adult Participants18 Years of Age and Older","status":"COMPLETED","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2022-12-12","conditions":"Influenza Immunization","enrollment":682},{"nctId":"NCT05624606","phase":"PHASE1, PHASE2","title":"Safety and Immunogenicity of Quadrivalent Influenza mRNA Vaccine MRT5410 in Adult Participants 18 Years of Age and Older","status":"COMPLETED","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2022-11-28","conditions":"Influenza Immunization","enrollment":682},{"nctId":"NCT03898986","phase":"PHASE1","title":"The Effects of Attenuated Versus Inactivated Flu Vaccine in Twin Sets","status":"COMPLETED","sponsor":"Stanford University","startDate":"2019-10-08","conditions":"Influenza","enrollment":18},{"nctId":"NCT03753347","phase":"PHASE4","title":"TITRE III: Influenza B Immunogenicity Investigation","status":"ACTIVE_NOT_RECRUITING","sponsor":"British Columbia Centre for Disease Control","startDate":"2018-12-01","conditions":"Influenza","enrollment":55},{"nctId":"NCT06622590","phase":"PHASE1","title":"Phase I Clinical Trial of Quadrivalent Influenza Virus Split Vaccine","status":"ACTIVE_NOT_RECRUITING","sponsor":"Institute of Medical Biology, Chinese Academy of Medical Sciences","startDate":"2024-10-13","conditions":"Influenza, Human, Influenza a, Influenza Type B","enrollment":180},{"nctId":"NCT05553301","phase":"PHASE1, PHASE2","title":"Safety and Immunogenicity of Quadrivalent Influenza mRNA Vaccine MRT5407 in Adult Participants18 Years of Age and Older","status":"COMPLETED","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2022-10-03","conditions":"Influenza Immunization","enrollment":560},{"nctId":"NCT05566639","phase":"PHASE3","title":"A Study of mRNA-1010 Seasonal Influenza Vaccine in Adults 50 Years Old and Older","status":"COMPLETED","sponsor":"ModernaTX, Inc.","startDate":"2022-09-14","conditions":"Seasonal Influenza","enrollment":22502},{"nctId":"NCT03849560","phase":"PHASE2, PHASE3","title":"Safety, Reactogenicity, Immunogenicity, Efficacy of Influenza Vaccines Grippol® Quadri and Grippol® Plus in Volunteers","status":"COMPLETED","sponsor":"NPO Petrovax","startDate":"2016-11","conditions":"Influenza","enrollment":612},{"nctId":"NCT05284799","phase":"PHASE2","title":"Immunogenicity and Safety of the Concomitant Administration of OVX836 and Quadrivalent Influenza Vaccine in Healthy Volunteers.","status":"COMPLETED","sponsor":"Osivax","startDate":"2022-05-09","conditions":"Influenza","enrollment":180},{"nctId":"NCT05895955","phase":"PHASE1, PHASE2","title":"Safety and Immunogenicity of GPO Seasonal Tetravalent Inactivated Split Virion Influenza Vaccine in Healthy Thais","status":"ACTIVE_NOT_RECRUITING","sponsor":"Mahidol University","startDate":"2023-11-04","conditions":"Influenza","enrollment":290},{"nctId":"NCT05415462","phase":"PHASE3","title":"A Study of mRNA-1010 Seasonal Influenza Vaccine in Adults","status":"COMPLETED","sponsor":"ModernaTX, Inc.","startDate":"2022-06-06","conditions":"Seasonal Influenza","enrollment":6102},{"nctId":"NCT05568797","phase":"PHASE3","title":"A Study on the Immune Response and Safety of a Vaccine Against Respiratory Syncytial Virus (RSV) When Given Alone or Co-administered With an Adjuvanted Vaccine Against Influenza in Adults Aged 65 Years and Above","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2022-10-14","conditions":"Respiratory Syncytial Virus Infections","enrollment":1045},{"nctId":"NCT05559476","phase":"PHASE3","title":"A Study on the Immune Response and Safety Elicited by a Vaccine Against Respiratory Syncytial Virus (RSV) When Given Alone and Together With a Vaccine Against Influenza in Adults Aged 65 Years and Above","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2022-10-20","conditions":"Respiratory Syncytial Virus Infections","enrollment":1029},{"nctId":"NCT03160118","phase":"PHASE4","title":"Study of Biomarkers of Immune Activation Associated with Symptoms and Immune Responses After Influenza Vaccination in Adults","status":"COMPLETED","sponsor":"University Hospital, Ghent","startDate":"2017-03-27","conditions":"Prevention of Influenza","enrollment":20},{"nctId":"NCT04576702","phase":"PHASE2","title":"Safety and Immunogenicity of an MF59-Adjuvanted Influenza Vaccine in Older Adults","status":"COMPLETED","sponsor":"Seqirus","startDate":"2020-10-08","conditions":"Influenza, Human","enrollment":471},{"nctId":"NCT05501561","phase":"PHASE2","title":"Safety and Immunogenicity of Different Formulations of an MF59-Adjuvanted Influenza Vaccine in Older Adults ≥50 Years of Age","status":"COMPLETED","sponsor":"Seqirus","startDate":"2022-08-25","conditions":"Influenza, Human","enrollment":1056},{"nctId":"NCT06091410","phase":"PHASE4","title":"Immunogenicity of Concomitant Administration of COVID-19 Vaccines With Influenza Vaccines","status":"ACTIVE_NOT_RECRUITING","sponsor":"Catholic Kwandong University","startDate":"2023-09-25","conditions":"COVID-19, Influenza, Vaccine Reaction","enrollment":62},{"nctId":"NCT05970887","phase":"PHASE4","title":"Immunogenicity and Safety of Concomitant Administration of Bivalent COVID-19 Vaccines With Influenza Vaccines","status":"COMPLETED","sponsor":"Catholic Kwandong University","startDate":"2022-10-12","conditions":"Immune Response, Safety","enrollment":154},{"nctId":"NCT05028361","phase":"PHASE4","title":"Simultaneous mRNA COVID-19 and IIV4 Vaccination Study","status":"COMPLETED","sponsor":"Duke University","startDate":"2021-10-04","conditions":"Quality of Life, Injection Site Reaction, Adverse Drug Event","enrollment":348},{"nctId":"NCT05409612","phase":"PHASE3","title":"Trial Assessing the Immunogenicity and Safety of Two Influenza Vaccine Strategies Among Severe Obese Adult Patients","status":"COMPLETED","sponsor":"Assistance Publique - Hôpitaux de Paris","startDate":"2022-11-07","conditions":"Morbid Obesity, Severe Obesity","enrollment":206},{"nctId":"NCT03457194","phase":"","title":"Optimising Protection for Pregnant Women and Infants With Maternal Vaccination","status":"UNKNOWN","sponsor":"Women's and Children's Hospital, Australia","startDate":"2018-08-28","conditions":"Obesity","enrollment":73},{"nctId":"NCT05734040","phase":"PHASE2","title":"Immunogenicity and Safety of the Concomitant Administration of OVX836 Influenza Vaccine, Quadrivalent Inactivated Influenza Vaccines and Placebo in Healthy Subjects.","status":"COMPLETED","sponsor":"Osivax","startDate":"2023-05-10","conditions":"Influenza","enrollment":478},{"nctId":"NCT06208683","phase":"PHASE4","title":"The Immunogenicity and Safety of the Booster Doses of a Live-attenuated Mumps Vaccine in Junior High School Students","status":"UNKNOWN","sponsor":"Sinovac Biotech Co., Ltd","startDate":"2023-11-04","conditions":"Mumps, Influenza","enrollment":400},{"nctId":"NCT05045144","phase":"PHASE3","title":"A Phase III Study to Assess the Lot-to-lot Consistency of GSK's Investigational RSV Maternal Vaccine and the Immune Response and Safety of RSV Maternal Vaccine When Given Alone or Co-administered With GSK's Influenza D-QIV Vaccine in Healthy Non-pregnant Women.","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2021-10-26","conditions":"Respiratory Syncytial Virus Infections","enrollment":1586},{"nctId":"NCT02677493","phase":"PHASE3","title":"Study to Evaluate the Immunogenicity and Safety of 'IL-YANG Quadrivalent Influenza Vaccine Inj.'","status":"COMPLETED","sponsor":"Il-Yang Pharm. Co., Ltd.","startDate":"2015-10","conditions":"Influenza","enrollment":1794},{"nctId":"NCT06029933","phase":"","title":"Fluad vs. Fluzone High-Dose Vaccine Effectiveness Among Adults ≥65 Years","status":"RECRUITING","sponsor":"Kaiser Permanente","startDate":"2023-08-17","conditions":"Influenza, Community-acquired Pneumonia, Cardiovascular Events","enrollment":960000},{"nctId":"NCT05739474","phase":"PHASE3","title":"Tolerability, Safety and Immunogenicity Trial of the Flu-M Tetra Vaccine in Children","status":"UNKNOWN","sponsor":"St. Petersburg Research Institute of Vaccines and Sera","startDate":"2022-01-19","conditions":"Influenza, Influenza, Human, Influenza Viral Infections","enrollment":948},{"nctId":"NCT03301051","phase":"PHASE3","title":"Efficacy, Safety, and Immunogenicity of a Plant-Derived Quadrivalent Virus-Like Particles (VLPs) Influenza Vaccine in Adults","status":"COMPLETED","sponsor":"Medicago","startDate":"2017-08-31","conditions":"Virus Diseases, RNA Virus Infections, Respiratory Tract Diseases","enrollment":10160},{"nctId":"NCT03321968","phase":"PHASE3","title":"Lot-to-lot Consistency of a Plant-Derived Quadrivalent Virus-Like Particles Influenza Vaccine in Healthy Adults","status":"COMPLETED","sponsor":"Medicago","startDate":"2017-09-29","conditions":"Virus Diseases, RNA Virus Infections, Respiratory Tract Infections","enrollment":1202},{"nctId":"NCT04622592","phase":"PHASE1, PHASE2","title":"Adjuvanted Seasonal Recombinant Quadrivalent Virus-Like Particles (QVLP) Influenza Vaccine in Adults 65 Years of Age and Older","status":"COMPLETED","sponsor":"Medicago","startDate":"2020-11-02","conditions":"Influenza","enrollment":209},{"nctId":"NCT03739112","phase":"PHASE3","title":"Efficacy of a Plant-derived Quadrivalent Virus-like Particle (VLP) Vaccine in the Elderly","status":"COMPLETED","sponsor":"Medicago","startDate":"2018-09-18","conditions":"Virus Diseases, RNA Virus Infections, Respiratory Tract Diseases","enrollment":12794},{"nctId":"NCT05062759","phase":"PHASE3","title":"Study to Assess the Effect of Tezepelumab on the Immune Response to Influenza Vaccination in Participants With Asthma","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2021-08-23","conditions":"Moderate to Severe Asthma","enrollment":70},{"nctId":"NCT05252338","phase":"PHASE1","title":"A Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Vaccine CVSQIV in Healthy Adults","status":"COMPLETED","sponsor":"CureVac","startDate":"2022-02-07","conditions":"Influenza","enrollment":240},{"nctId":"NCT05869201","phase":"PHASE2, PHASE3","title":"Tolerability, Safety and Immunogenicity Trial of the Flu-M Quadro, Tetravalent Inactivated Split Influenza Vaccine","status":"COMPLETED","sponsor":"St. Petersburg Research Institute of Vaccines and Sera","startDate":"2020-10-06","conditions":"Influenza, Influenza, Human, Influenza Viral Infections","enrollment":450},{"nctId":"NCT04120194","phase":"PHASE3","title":"Phase 3 Pivotal Trial of NanoFlu™ in Older Adults","status":"COMPLETED","sponsor":"Novavax","startDate":"2019-10-14","conditions":"Influenza, Human","enrollment":2654},{"nctId":"NCT03430089","phase":"PHASE1","title":"Safety of a Single Dose or Two Doses of Shenzhen Quadrivalent Influenza Vaccine","status":"COMPLETED","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2019-02-22","conditions":"Influenza, Flu","enrollment":101},{"nctId":"NCT05212623","phase":"PHASE1","title":"A Clinical Trial of an Quadrivalent Inactivated Influenza Vaccine in Healthy Children Aged 6 to 35 Months","status":"COMPLETED","sponsor":"Jiangsu Province Centers for Disease Control and Prevention","startDate":"2021-10-26","conditions":"Influenza","enrollment":120},{"nctId":"NCT04192500","phase":"PHASE2","title":"Safety and Immune Response of One Dose of OVX836 at Two Dose Levels, in Comparison to Influvac TetraTM, After Intramuscular Administration in Healthy Subjects Aged 18-65 Years","status":"COMPLETED","sponsor":"Osivax","startDate":"2019-12-11","conditions":"Influenza","enrollment":300},{"nctId":"NCT05048589","phase":"PHASE2","title":"Feasibility of Randomizing Danish Citizens Aged 65-79 Years to High-Dose Quadrivalent Influenza Vaccine vs. Standard-Dose Quadrivalent Influenza Vaccine in a Pragmatic Registry-Based Setting","status":"COMPLETED","sponsor":"Tor Biering-Sørensen","startDate":"2021-10-01","conditions":"Influenza","enrollment":12551},{"nctId":"NCT05499351","phase":"PHASE4","title":"A Study of Booster Immunization With COVID-19 Vaccine,Inactivated Co -Administration With Influenza Vaccine and Pneumococcal Polysaccharide Vaccine","status":"COMPLETED","sponsor":"Sinovac Biotech Co., Ltd","startDate":"2021-10-15","conditions":"COVID-19","enrollment":3000},{"nctId":"NCT04559204","phase":"PHASE4","title":"Evaluation of Safety and Immunogenicity of Combined Immunization of PPV23 and IIV4","status":"COMPLETED","sponsor":"China National Biotec Group Company Limited","startDate":"2020-09-11","conditions":"Influenza, Human, Pneumonia, Pneumococcal","enrollment":1224},{"nctId":"NCT04077424","phase":"PHASE4","title":"Senescent Immunity in Elders and Vaccine Responses (SILVER)","status":"COMPLETED","sponsor":"Vanderbilt University Medical Center","startDate":"2019-10-21","conditions":"Flu Vaccine","enrollment":10},{"nctId":"NCT03391193","phase":"PHASE3","title":"Immunogenicity and Safety of a Multi-Dose Quadrivalent Influenza Vaccine","status":"COMPLETED","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2017-12-19","conditions":"Influenza","enrollment":301},{"nctId":"NCT02451358","phase":"PHASE3","title":"Study of a Single Dose or Two Doses of a Quadrivalent Influenza Vaccine in Subjects Aged 6 Months or Older in India","status":"COMPLETED","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2015-07-27","conditions":"Influenza","enrollment":400},{"nctId":"NCT03282240","phase":"PHASE3","title":"Safety and Immunogenicity of High-Dose Quadrivalent Influenza Vaccine in Participants ≥65 Years in the US","status":"COMPLETED","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2017-09-08","conditions":"Influenza","enrollment":2670},{"nctId":"NCT03698279","phase":"PHASE2","title":"Safety and Immunogenicity of Different Dosages of High-Dose Quadrivalent Influenza Vaccine in Children 6 Months to 17 Years of Age","status":"COMPLETED","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2018-10-09","conditions":"Influenza","enrollment":665},{"nctId":"NCT03233217","phase":"PHASE1, PHASE2","title":"Safety and Immunogenicity of High-Dose Quadrivalent Influenza Vaccine in Patients ≥65 Years","status":"COMPLETED","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2017-09-15","conditions":"Influenza","enrollment":175},{"nctId":"NCT03553940","phase":"PHASE1","title":"H3N2 M2SR in Pediatric Population","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2018-08-15","conditions":"Influenza, Influenza Immunisation","enrollment":43},{"nctId":"NCT04790851","phase":"PHASE4","title":"Evaluation of Immunogenicity and Safety of Combined Immunization of COVID-19 Vaccine (Produced in Beijing) and PPV23 / IIV4","status":"COMPLETED","sponsor":"China National Biotec Group Company Limited","startDate":"2021-03-10","conditions":"Influenza, Human, Pneumonia, Pneumococcal, Covid19","enrollment":1133},{"nctId":"NCT05079152","phase":"PHASE4","title":"Evaluation of Immunogenicity and Safety of Combined Immunization of COVAX (Produced in Wuhan) and PPV23 / IIV4","status":"UNKNOWN","sponsor":"China National Biotec Group Company Limited","startDate":"2021-05-06","conditions":"Influenza, Human, Pneumonia, Pneumococcal, COVID-19 Pneumonia","enrollment":1404},{"nctId":"NCT04984408","phase":"PHASE3","title":"Efficacy, Immunogenicity and Safety of BBIBP-CorV Vaccine Against Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection.","status":"UNKNOWN","sponsor":"International Vaccine Institute","startDate":"2021-10-01","conditions":"COVID-19 Disease","enrollment":8825},{"nctId":"NCT04143451","phase":"PHASE3","title":"Intradermal Influenza Vaccine With Topical Imiquimod in Elderly and Chronic Illness Patients","status":"UNKNOWN","sponsor":"The University of Hong Kong","startDate":"2019-10-23","conditions":"Influenza","enrollment":4000},{"nctId":"NCT03600428","phase":"PHASE4","title":"Safety of LAIV4 in Children With Asthma","status":"COMPLETED","sponsor":"Vanderbilt University Medical Center","startDate":"2018-10-15","conditions":"Asthma in Children, Vaccine Adverse Reaction, Vaccine Reaction","enrollment":152},{"nctId":"NCT03448705","phase":"PHASE1","title":"Safety of 4Fluart ID Suspension for Injection in Adult Subjects","status":"COMPLETED","sponsor":"Fluart Innovative Vaccine Ltd, Hungary","startDate":"2018-01-31","conditions":"Human Influenza","enrollment":36},{"nctId":"NCT02480998","phase":"PHASE1, PHASE2","title":"Study to Evaluate the Safety and Immunogenicity of 'IL-YANG Flu Vaccine Quadrivalent Inj' in Healthy Korean Adults","status":"COMPLETED","sponsor":"Il-Yang Pharm. Co., Ltd.","startDate":"2015-02","conditions":"Influenza, Human","enrollment":84},{"nctId":"NCT03926416","phase":"PHASE1","title":"Safety Study of Live Attenuated Influenza Vaccine, CodaVax","status":"COMPLETED","sponsor":"Codagenix, Inc","startDate":"2017-02-21","conditions":"Influenza","enrollment":125},{"nctId":"NCT03058692","phase":"PHASE2","title":"Two Doses of Multimeric-001 (M-001) Followed by Influenza Vaccine","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2018-04-09","conditions":"Influenza, Influenza Immunisation","enrollment":120},{"nctId":"NCT01991587","phase":"PHASE1, PHASE2","title":"Safety, Tolerability and Immunogenicity of a Plant-made Seasonal Quadrivalent VLP Influenza Vaccine in Adults","status":"COMPLETED","sponsor":"Medicago","startDate":"2013-10-08","conditions":"Virus Diseases, RNA Virus Infections, Respiratory Tract Diseases","enrollment":120},{"nctId":"NCT02768805","phase":"PHASE2","title":"Immunogenicity of a Quadrivalent Virus-Like Particles (VLP) Influenza Vaccine in Healthy Adults","status":"COMPLETED","sponsor":"Medicago","startDate":"2016-03-02","conditions":"Virus Diseases, RNA Virus Infections, Respiratory Tract Diseases","enrollment":900},{"nctId":"NCT03445468","phase":"PHASE3","title":"Immunogenicity and Safety for 'IL-YANG Quadrivalent Influenza Vaccine' in Healthy Korean Children and Adolescents","status":"COMPLETED","sponsor":"Il-Yang Pharm. Co., Ltd.","startDate":"2017-09-20","conditions":"Influenza, Human","enrollment":379},{"nctId":"NCT02467842","phase":"PHASE3","title":"Immunogenicity and Safety of Quadrivalent Influenza Vaccine (NBP607-QIV) in Adults and Elderly Subjects","status":"COMPLETED","sponsor":"SK Chemicals Co., Ltd.","startDate":"2014-10","conditions":"Influenza","enrollment":1503},{"nctId":"NCT03701061","phase":"PHASE4","title":"Durability and Impact of the Seasonal Influenza Vaccine on H5 Induced B Cell Response","status":"COMPLETED","sponsor":"Emory University","startDate":"2018-10-11","conditions":"Influenza A Subtype H5N1 Infection","enrollment":12},{"nctId":"NCT03453801","phase":"PHASE1","title":"The Role of CD4+ Memory Phenotype, Memory, and Effector T Cells in Vaccination and Infection","status":"COMPLETED","sponsor":"Stanford University","startDate":"2014-09-30","conditions":"Influenza, Healthy","enrollment":80},{"nctId":"NCT03088904","phase":"PHASE1","title":"Genetic and Environmental Factors in the Response to Influenza Vaccination","status":"COMPLETED","sponsor":"Stanford University","startDate":"2014-10-03","conditions":"Influenza, Healthy","enrollment":109},{"nctId":"NCT03564444","phase":"PHASE4","title":"D2560C00015 FluMist Annual Safety Study 2018","status":"COMPLETED","sponsor":"MedImmune LLC","startDate":"2018-06-06","conditions":"Influenza, Healthy","enrollment":300},{"nctId":"NCT02233816","phase":"PHASE2","title":"Immunogenicity, Safety and Tolerability of a Plant-Derived Seasonal Virus-Like-Particle Quadrivalent Influenza Vaccine in Adults","status":"COMPLETED","sponsor":"Medicago","startDate":"2014-07-28","conditions":"Virus Diseases, RNA Virus Infections, Respiratory Tract Diseases","enrollment":300},{"nctId":"NCT03460743","phase":"PHASE3","title":"Evaluation of a Recombinant Quadrivalent Influenza Vaccine Versus a Marketed Quadrivalent Inactivated Influenza Vaccine in Children 3 to 17.","status":"COMPLETED","sponsor":"Laboratorios Liomont","startDate":"2018-03-22","conditions":"Influenza, Human","enrollment":1556}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":20,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["VaxigripTetra"],"phase":"phase_3","status":"active","brandName":"Single-dose Quadrivalent Influenza Vaccine","genericName":"Single-dose Quadrivalent Influenza Vaccine","companyName":"Sanofi Pasteur, a Sanofi Company","companyId":"sanofi","modality":"Biologic","firstApprovalDate":"","aiSummary":"This vaccine induces an immune response against four different influenza viruses. Used for Prevention of influenza disease caused by four different strains of the influenza virus.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":1,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}